Editas Medicine, Inc. (NasdaqGS: EDIT)
Health Care · Biotechnology · US
$2.84
+3.27% today · -31.6% 1Y
Editas Medicine, Inc. (NasdaqGS: EDIT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $436.17M and employs 87 people.
Over the last twelve months the share price has lost 31.6%, trading between 1.66 and 4.54.
Tweenvest scores Editas Medicine, Inc. across four factors: quality 36/100, value 70/100, growth 100/100. Its strongest factor is growth.
EDIT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $436.17M
- Revenue (TTM)
- $47.01M
- P/E
- —
- EPS
- -0.73
- Dividend yield
- —
- Beta (5Y)
- 2.00
- 52-week high
- $4.54
- 52-week low
- $1.66
- Avg volume (3M)
- —
- Shares outstanding
- 153.58M
- Employees
- 87
- Next earnings
- —
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
- ISIN
- US28106W1036
- Founded
- 2013
- Listed since
- Feb 3, 2016
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Avacta Group PlcAIM: AVCT | $445.37M | £0.64 | -11.11% |
| DiaMedica Therapeutics Inc.NasdaqCM: DMAC | $443.81M | $8.01 | -2.67% |
| Tectonic Therapeutic, Inc.NasdaqGM: TECX | $440.64M | $22.75 | +0.93% |
| Hubei Goto Biopharm Group Co., Ltd.SZSE: 300966 | $437.59M | CN¥25.70 | +0.86% |
| Myriad Genetics, Inc.NasdaqGS: MYGN | $434.25M | $4.20 | -7.49% |
| Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd.SZSE: 300313 | $431.10M | CN¥12.06 | -2.51% |
| Edding Genor Group Holdings LimitedSEHK: 6998 | $430.01M | HK$1.70 | +1.80% |
| Prothena Corporation plcNasdaqGS: PRTA | $429.18M | $8.61 | +2.99% |
Figures last refreshed Oct 4, 2026.